ENTITY
China Biologic Products

China Biologic Products (CBPO US)

27
Analysis
Health CareUnited States
China Biologic Products Holdings, Inc. operates as a biopharmaceutical company. The Company researches, develops, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. China Biologic Products also distributes pharmaceutical products. China Biologic Products serves clients in China.
more
Refresh
24 Sep 2019 04:33

Last Week in GER Research: Topsports, Bitauto, Cloudminds, Manulife, Maple Ind. Trust and Budweiser

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week, we assess the IPO prospects for...

Logo
460 Views
Share
20 Sep 2019 03:06

China Biologic's Privatisation Redux

On Wednesday after market close, China Biologic Products (CBPO US) announced a surprising privatisation bid from a consortium for $120 per ADS. The...

Logo
492 Views
Share
19 Sep 2019 13:01

Vital Fluids: Proposal Rejuvenates China Biologics

On the 19 June last year, CITIC Capital Holdings made an unsolicited, preliminary non-binding proposal for China Biologic Products (CBPO US) - a...

Logo
570 Views
Share
12 Aug 2019 09:31

Global Equity Strategy: Another Test of Support

Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no...

Logo
387 Views
Share
19 Mar 2019 03:30

China Blood Products: Deals Highlight Values

Grifols SA (GRF SM) and Shanghai RAAS Blood Products Co Ltd (002252.SZ) recently announced an asset exchange that effectively combines the...

Share
x